DNA Repair Protein Biomarkers Associated with Time to Recurrence in Triple-Negative Breast Cancer

被引:27
作者
Alexander, Brian M. [1 ,2 ]
Sprott, Kam [3 ]
Farrow, D. Allan [3 ]
Wang, XiaoZhe [3 ]
D'Andrea, Alan D. [1 ]
Schnitt, Stuart J. [4 ]
Collins, Laura C. [4 ]
Weaver, David T. [3 ]
Garber, Judy E. [5 ]
机构
[1] Harvard Univ, Sch Med, Dept Radiat Oncol, Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA
[2] Harvard Radiat Oncol Program, Boston, MA USA
[3] On Q Ity Inc, Waltham, MA USA
[4] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA
[5] Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA
关键词
FANCONI-ANEMIA; HOMOLOGOUS RECOMBINATION; INCREASED SENSITIVITY; MAPKAP KINASE-2; CISPLATIN; MUTATIONS; SUBTYPES; DAMAGE; CELLS; GENE;
D O I
10.1158/1078-0432.CCR-10-0292
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the prognostic utility of immunohistochemical assessment of key proteins in multiple DNA repair pathways in triple-negative breast cancer (TNBC; estrogen receptor negative, progesterone receptor negative, and HER2/neu negative by immunohistochemistry). Experimental Design: Archived clinically annotated tumor specimens from 112 women with TNBC were immunostained with antibodies against DNA repair proteins and scored using digital image analysis. The cohort was divided into training and test sets for development of a multiantibody model. Scores were combined with clinical data to assess association with outcome. Results: Low XPF (P = 0.005), pMK2 (P = 0.01), MLH; P = 0.002), and FANCD2 (P = 0.001) were each associated with shorter time to recurrence (TTR) in univariate analysis. A 4-antibody model could segregate high-risk and low-risk groups on the basis of TTR in both the training (relative risk [RR] = 3.52; P = 9.05E-07) and test (RR 2.67; P = 0.019) cohorts. Conclusions: DNA repair proteins may be useful as prognostic markers in TNBC. Further study in larger, uniformly treated cohorts with additional clinical parameters is warranted. Clin Cancer Res; 16(23); 5796-804. (C)2010 AACR.
引用
收藏
页码:5796 / 5804
页数:9
相关论文
共 56 条
[1]   Integrated profiling of basal and luminal breast cancers [J].
Adelaide, Jose ;
Finetti, Pascal ;
Bekhouche, Ismahane ;
Repellini, Laetitia ;
Geneix, Jeannine ;
Sircoulomb, Fabrice ;
Jauffret, Emmanuelle Charafe ;
Cervera, Nathalie ;
Desplans, Jerome ;
Parzy, Daniel ;
Schoenmakers, Eric ;
Viens, Patrice ;
Jacquemier, Jocelyne ;
Birnbaum, Daniel ;
Bertucci, Francois ;
Chaffanet, Max .
CANCER RESEARCH, 2007, 67 (24) :11565-11575
[2]   A role for polymerase η in the cellular tolerance to cisplatin-induced damage [J].
Albertella, MR ;
Green, CM ;
Lehmann, AR ;
O'Connor, MJ .
CANCER RESEARCH, 2005, 65 (21) :9799-9806
[3]   Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array [J].
Andre, Fabrice ;
Job, Bastien ;
Dessen, Philippe ;
Tordai, Attila ;
Michiels, Stefan ;
Liedtke, Cornelia ;
Richon, Catherine ;
Yan, Kai ;
Wang, Bailang ;
Vassal, Gilles ;
Delaloge, Suzette ;
Hortobagyi, Gabriel N. ;
Symmans, W. Fraser ;
Lazar, Vladimir ;
Pusztai, Lajos .
CLINICAL CANCER RESEARCH, 2009, 15 (02) :441-451
[4]   Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial [J].
Audeh, M. William ;
Carmichael, James ;
Penson, Richard T. ;
Friedlander, Michael ;
Powell, Bethan ;
Bell-McGuinn, Katherine M. ;
Scott, Clare ;
Weitzel, Jeffrey N. ;
Oaknin, Ana ;
Loman, Niklas ;
Lu, Karen ;
Schmutzler, Rita K. ;
Matulonis, Ursula ;
Wickens, Mark ;
Tutt, Andrew .
LANCET, 2010, 376 (9737) :245-251
[5]   Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer [J].
Bergamaschi, Anna ;
Kim, Young H. ;
Wang, Pei ;
Sorlie, Therese ;
Hernandez-Boussard, Tina ;
Lonning, Per E. ;
Tibshirani, Robert ;
Borresen-Dale, Anne-Lise ;
Pollack, Jonathan R. .
GENES CHROMOSOMES & CANCER, 2006, 45 (11) :1033-1040
[6]   XPF-ERCC1 Participates in the Fanconi Anemia Pathway of Cross-Link Repair [J].
Bhagwat, Nikhil ;
Olsen, Anna L. ;
Wang, Anderson T. ;
Hanada, Katsuhiro ;
Stuckert, Patricia ;
Kanaar, Roland ;
D'Andrea, Alan ;
Niedernhofer, Laura J. ;
McHugh, Peter J. .
MOLECULAR AND CELLULAR BIOLOGY, 2009, 29 (24) :6427-6437
[7]   Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair [J].
Bryant, HE ;
Helleday, T .
NUCLEIC ACIDS RESEARCH, 2006, 34 (06) :1685-1691
[8]   Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J].
Bryant, HE ;
Schultz, N ;
Thomas, HD ;
Parker, KM ;
Flower, D ;
Lopez, E ;
Kyle, S ;
Meuth, M ;
Curtin, NJ ;
Helleday, T .
NATURE, 2005, 434 (7035) :913-917
[9]   Human cells deficient in transcription-coupled repair show prolonged activation of the Jun N-terminal kinase and increased sensitivity following cisplatin treatment [J].
Bulmer, JT ;
Zacal, NJ ;
Rainbow, AJ .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (02) :189-198
[10]   Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients [J].
Byrski, T. ;
Huzarski, T. ;
Dent, R. ;
Gronwald, J. ;
Zuziak, D. ;
Cybulski, C. ;
Kladny, J. ;
Gorski, B. ;
Lubinski, J. ;
Narod, S. A. .
BREAST CANCER RESEARCH AND TREATMENT, 2009, 115 (02) :359-363